Where no man has gone before: the technologies being used to explore MM epigenetic factors

In recent years, researchers have become increasingly aware of the fact that epigenetic alterations can contribute to the formation of multiple myeloma (MM); however, our understanding of these remain... Author: VJHemOnc Added: 12/06/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

to “Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma” [Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):210-218]
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Tags: Information Item Source Type: research
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Source Type: research
Publication date: August 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 8Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: August 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 8Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: August 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 8Author(s):
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractThere is paucity of data from developing countries on the clinical outcomes in myeloma post-autologous transplantation. In this retrospective study, we used hospital records to retrieve data of patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) from January 1995 to December 2014 at our centre. During the study period, 245 patients underwent ASCT for myeloma. Of these, 19%, 37% and 37% were in complete response, very good partial response and partial response respectively at the time of ASCT. Only in 14 (5.7%) patients, the stem cells were cryopreserved. The transplant related mort...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Publication date: Available online 18 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kian J. Rahbari, Jason D. Nosrati, Tanya M. Spektor, James R. Berenson
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAlthough patients with MYC-R lymphoma have been reported to be at high risk of primary treatment failure, this was not predicted by iPET+ results. Thus, the iPET result should not be used to guide changes in front-line or consolidative therapy for these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Monoclonal antibodies are an exciting theapeutic avenue for hematological cancers, including multiple myeloma (MM). Here, Neils van de Donk, MD, PhD, of VU University Medical Centre, Amsterdam, Nether... Author: VJHemOnc Added: 07/20/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Myeloma